Citadel Advisors’s Lipocine LPCN Stock Holding History

Citadel Advisors’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-53	Closed	-$286	–	14859
2023 Q1	$286	Sell	53 -665	-93%	-$5.14K	﹤0.01%	14527
2022 Q4	$4.68K	Sell	718 -6	-0.8%	-$44	﹤0.01%	14077
2022 Q3	$6K	Buy	724 +12	+2%	+$134	﹤0.01%	12347
2022 Q2	$10K	Sell	712 -1,759	-71%	-$27.4K	﹤0.01%	12578
2022 Q1	$58K	Buy	2,471 +1,036	+72%	+$21.7K	﹤0.01%	12698
2021 Q4	$24K	Sell	1,435 -1,700	-54%	-$31.6K	﹤0.01%	13542
2021 Q3	$58K	Sell	3,135 -118	-4%	-$2.6K	﹤0.01%	13286
2021 Q2	$77K	Sell	3,253 -2,076	-39%	-$48.8K	﹤0.01%	13101
2021 Q1	$137K	Buy	+5,329	New	+$154K	﹤0.01%	12151
2019 Q4	–	Sell	-682	Closed	-$33K	–	9467
2019 Q3	$33K	Buy	+682	New	+$27.4K	﹤0.01%	8823

Other funds holding LPCN

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $318M AUM

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Citadel Advisors's LPCN Position: Q1 2026 in Review

Citadel Advisors opened a new position in Lipocine (LPCN) in Q1 2026: 29,088 shares worth $232K. The stake represents ﹤0.01% of the portfolio and ranks #11090 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in LPCN as recently as Q3 2025.

Citadel Advisors first reported a position in LPCN in Q3 2015 and has held it in 16 quarters since. The position peaked at $820K in Q3 2015. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

Citadel Advisors held 29,088 shares of Lipocine worth $232K as of Q1 2026.
Lipocine was a new Citadel Advisors position in Q1 2026.
Lipocine made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11090 holding.
Citadel Advisors first reported a position in Lipocine in Q3 2015 and has held it in 16 quarters since.
Citadel Advisors's Lipocine position peaked at $820K in Q3 2015.
47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.